IFG Advisory’s Supernus Pharmaceuticals SUPN Stock Holding History

IFG Advisory’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,034	Closed	-$388K	–	526
2022 Q1	$388K	Sell	12,034 -879	-7%	-$26.9K	0.04%	346
2021 Q4	$376K	Sell	12,913 -771	-6%	-$23.4K	0.04%	362
2021 Q3	$364K	Hold	13,684	–	–	0.04%	356
2021 Q2	$421K	Buy	+13,684	New	+$420K	0.05%	327

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

IFG Advisory's SUPN Position: Q2 2022 in Review

IFG Advisory sold out of Supernus Pharmaceuticals (SUPN) in Q2 2022, closing a stake of 12,034 shares — an estimated $388K sold.

IFG Advisory first reported a position in SUPN in Q2 2021 and held it in 4 quarters. The position peaked at $421K in Q2 2021. 225 funds tracked by Wall St. Rank hold SUPN as of Q2 2022.

IFG Advisory reported no remaining Supernus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
IFG Advisory sold 12,034 Supernus Pharmaceuticals shares in Q2 2022, an estimated $388K.
IFG Advisory first reported a position in Supernus Pharmaceuticals in Q2 2021 and held it in 4 quarters.
IFG Advisory's Supernus Pharmaceuticals position peaked at $421K in Q2 2021.
225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2022.

Based on IFG Advisory's 13F filing for Q2 2022, filed 4 Aug 2022.